{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:48:55Z","timestamp":1770979735201,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":73,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642179686","type":"print"},{"value":"9783642179693","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-3-642-17969-3_13","type":"book-chapter","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T11:32:33Z","timestamp":1308655953000},"page":"307-322","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase Inhibitors"],"prefix":"10.1007","author":[{"given":"Stefan","family":"\u00dcckert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,6]]},"reference":[{"key":"13_CR1_13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0090-4295(99)80291-X","volume":"46","author":"JT Andersen","year":"1995","unstructured":"Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K (1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 46:631\u2013637","journal-title":"Urology"},{"key":"13_CR2_13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.juro.2008.06.070","volume":"180","author":"KE Andersson","year":"2008","unstructured":"Andersson KE (2008) How many drugs for LUTS due to BPH are too many? J Urol 180:811\u2013812","journal-title":"J Urol"},{"key":"13_CR3_13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/PL00007101","volume":"19","author":"KE Andersson","year":"2001","unstructured":"Andersson KE, Chapple C, Wein A (2001) The basis for drug treament of the overactive bladder. World J Urol 19:294\u2013298","journal-title":"World J Urol"},{"key":"13_CR4_13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1006\/frne.1999.0193","volume":"21","author":"FA Antoni","year":"2000","unstructured":"Antoni FA (2000) Molecular diversity of cAMP signaling. Front Neuroendocrinol 21:103\u2013132","journal-title":"Front Neuroendocrinol"},{"key":"13_CR5_13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0022-5347(01)62833-7","volume":"160","author":"AJ Becker","year":"1998","unstructured":"Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U (1998) The effect of the specific phosphodiesterase 4 inhibitor rolipram on the ureteral peristalsis in vitro and in vivo. J Urol 160:920\u2013925","journal-title":"J Urol"},{"key":"13_CR6_13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0022-5347(01)66199-8","volume":"155","author":"D Cahn","year":"1997","unstructured":"Cahn D, Melman A, Valcic M, Christ GJ (1997) Forskolin: a promising new adjunct to intracavernous pharmacotherapy. J Urol 155:1789\u20131794","journal-title":"J Urol"},{"key":"13_CR7_13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0022-5347(01)66254-2","volume":"155","author":"TN Chiricos","year":"1996","unstructured":"Chiricos TN, Sanford E (1996) Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 155:1311\u20131316","journal-title":"J Urol"},{"key":"13_CR8_13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6603(08)60718-7","volume":"63","author":"M Conti","year":"1999","unstructured":"Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1\u201338","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"13_CR9_13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1742-1241.2002.tb11260.x","volume":"56","author":"I Eardly","year":"2002","unstructured":"Eardly I, Cartledge J (2002) Tadalafil (CIALIS) for men with erectile dysfunction. Int J Clin Pract 56:300\u2013304","journal-title":"Int J Clin Pract"},{"issue":"Suppl. H","key":"13_CR10_13","doi-asserted-by":"crossref","first-page":"H32","DOI":"10.1016\/S1520-765X(02)90050-7","volume":"4","author":"JT Emmick","year":"2002","unstructured":"Emmick JT, Stuewe SR, Mitchell M (2002) Overview of the cardiovascular effects of tadalafil. Eur Heart J 4(suppl H):H32\u2013H47","journal-title":"Eur Heart J"},{"key":"13_CR11_13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1067\/mai.2001.119555","volume":"108","author":"DM Essayan","year":"2001","unstructured":"Essayan DM (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108:671\u2013680","journal-title":"J Allergy Clin Immunol"},{"key":"13_CR12_13","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1073\/pnas.050585197","volume":"97","author":"L Fawcett","year":"2000","unstructured":"Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Philips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702\u20133707","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR13_13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/archinte.162.12.1349","volume":"162","author":"HA Fink","year":"2002","unstructured":"Fink HA, McDonald R, Rutks IR, Nelson DB, Wilt TJ (2002) Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 162:1349\u20131360","journal-title":"Arch Intern Med"},{"key":"13_CR14_13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1006\/bbrc.1998.8684","volume":"246","author":"AD Fisher","year":"1998","unstructured":"Fisher AD, Smith JF, Pillar JS, St Denis S, Cheng JB (1998a) Isolation and characterization of PDE8A, a novel cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246:570\u2013577","journal-title":"Biochem Biophys Res Commun"},{"key":"13_CR15_13","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","volume":"273","author":"AD Fisher","year":"1998","unstructured":"Fisher AD, Smith JF, Pillar JS, St Denis S, Cheng JB (1998b) Isolation and characterization of PDE9A, a novel cGMP-specific phosphodiesterase. J Biol Chem 273:15559\u201315564","journal-title":"J Biol Chem"},{"key":"13_CR16_13","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.juro.2007.07.048","volume":"178","author":"M Gacci","year":"2007","unstructured":"Gacci M, del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M (2007) Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178:2040\u20132043","journal-title":"J Urol"},{"key":"13_CR17_13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1743-6109.2008.01079.x","volume":"6","author":"S Glina","year":"2009","unstructured":"Glina S, Toscano I, Gomatzky C, de Goes PM, Junior AN, Claro JF, Pagani E (2009) Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 6:553\u2013557","journal-title":"J Sex Med"},{"key":"13_CR18_13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00240-006-0073-1","volume":"35","author":"C Gratzke","year":"2007","unstructured":"Gratzke C, \u00dcckert S, Kedia G, Reich O, Schlenker B, Seitz M, Becker AJ, Stief CG (2007) In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 35:49\u201354","journal-title":"Urol Res"},{"key":"13_CR19_13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.eururo.2006.06.049","volume":"50","author":"EA Greco","year":"2006","unstructured":"Greco EA, Spera G, Aversa A (2006) Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 50:940\u2013947","journal-title":"Eur Urol"},{"key":"13_CR20_13","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S0960-894X(02)00190-7","volume":"12","author":"D Guay","year":"2002","unstructured":"Guay D, Hamel P, Blouin M, Brideau C, Chan CC, Chauret N, Ducharme Y, Huang Z, Girard M, Jones TR, Laliberte F, Masson P, McAuliffe M, Piechuta H, Silva J, Young RN, Girard Y (2002) Discovery of L-791.943: a potent, selective, non-emetic and orally active phosphodiesterase 4 inhibitor. Bioorg Med Chem Lett 12:1457\u20131461","journal-title":"Bioorg Med Chem Lett"},{"key":"13_CR21_13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0094-0143(21)00662-5","volume":"22","author":"HA Guess","year":"1995","unstructured":"Guess HA (1995) Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 22:247\u2013261","journal-title":"Urol Clin North Am"},{"key":"13_CR22_13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000112611","volume":"80","author":"C G\u00fclcer","year":"2008","unstructured":"G\u00fclcer C, T\u00fczel E, Dogantekin E, Kiziltepe G (2008) Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 80:181\u2013185","journal-title":"Urol Int"},{"key":"13_CR23_13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/13543784.17.6.855","volume":"17","author":"S Gur","year":"2008","unstructured":"Gur S, Sikka SC, Hellstrom WJ (2008) Novel phosphodiesterase 5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs 17:855\u2013864","journal-title":"Expert Opin Investig Drugs"},{"key":"13_CR24_13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/sj.ijir.3901290","volume":"17","author":"P Gutierrez","year":"2005","unstructured":"Gutierrez P, Hernandez P, Mas M (2005) Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil non-responders. Int J Impot Res 17:354\u2013358","journal-title":"Int J Impot Res"},{"key":"13_CR25_13","doi-asserted-by":"publisher","first-page":"16152","DOI":"10.1074\/jbc.272.26.16152","volume":"272","author":"P Han","year":"1997","unstructured":"Han P, Zhu X, Michaeli T (1997) Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 272:16152\u201316157","journal-title":"J Biol Chem"},{"key":"13_CR26_13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00003495-200868020-00006","volume":"68","author":"K Hatzimouratidis","year":"2008","unstructured":"Hatzimouratidis K, Hatzichristou DG (2008) Looking to the future for erectile dysfunction therapies. Drugs 68:231\u2013250","journal-title":"Drugs"},{"key":"13_CR27_13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-5347(17)40074-7","volume":"143","author":"JP Heaton","year":"1990","unstructured":"Heaton JP, Morales A, Owen J (1990) Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. J Urol 143:729\u2013731","journal-title":"J Urol"},{"key":"13_CR28_13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/phrs.1996.0022","volume":"33","author":"JR Hieble","year":"1996","unstructured":"Hieble JR, Ruffolo RR Jr (1996) The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hyperplasia: an overview. Pharmacol Res 33:145\u2013160","journal-title":"Pharmacol Res"},{"key":"13_CR29_13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1748-1716.1991.tb09236.x","volume":"143","author":"F Holmquist","year":"1991","unstructured":"Holmquist F, Stief CG, Jonas U, Andersson KE (1991) Effects of the nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand 143:299\u2013304","journal-title":"Acta Physiol Scand"},{"key":"13_CR30_13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archfami.2.7.729","volume":"2","author":"SJ Jacobsen","year":"1993","unstructured":"Jacobsen SJ, Guess HA, Panser L, Girman CJ, Chute CG, Oesterling JE, Lieber MM (1993) A population-based study of health care-seeking behaviour for treatment of urinary symptoms. Arch Fam Med 2:729\u2013735","journal-title":"Arch Fam Med"},{"key":"13_CR31_13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1468-3083.2004.00885.x","volume":"18","author":"JS Kalsi","year":"2004","unstructured":"Kalsi JS, Kell PD (2004) Update on the oral treatments for male erectile dysfunction. J Eur Acad Dermatol Venereol 18:267\u2013274","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"13_CR32_13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.ijir.3901331","volume":"17","author":"KK Kang","year":"2005","unstructured":"Kang KK, Yu JY, Yoo M, Kwon JW (2005) The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res 17:409\u2013416","journal-title":"Int J Impot Res"},{"key":"13_CR33_13","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","volume":"51","author":"SA Kaplan","year":"2007","unstructured":"Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717\u20131723","journal-title":"Eur Urol"},{"key":"13_CR34_13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s002400050147","volume":"28","author":"R K\u00fchn","year":"2000","unstructured":"K\u00fchn R, \u00dcckert S, Stief CG, Truss MC, Lietz B, Bischoff E, Schramm M, Jonas U (2000) Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide dependent pathways. Urol Res 28:110\u2013115","journal-title":"Urol Res"},{"key":"13_CR35_13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000020262","volume":"38","author":"A K\u00fcthe","year":"2000","unstructured":"K\u00fcthe A, M\u00e4gert HJ, \u00dcckert S, Forssmann WG, Stief CG, Jonas U (2000) Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 38:108\u2013114","journal-title":"Eur Urol"},{"key":"13_CR36_13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00005392-200101000-00079","volume":"165","author":"A K\u00fcthe","year":"2001","unstructured":"K\u00fcthe A, Wiedenroth A, M\u00e4gert HJ, \u00dcckert S, Forssmann WG, Stief CG, Jonas U (2001) Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol 165:280\u2013283","journal-title":"J Urol"},{"key":"13_CR37_13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1743-6109.2008.01109.x","volume":"6","author":"G Liguori","year":"2009","unstructured":"Liguori G, Trombetta C, de Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E (2009) Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 6:544\u2013552","journal-title":"J Sex Med"},{"key":"13_CR38_13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","volume":"234","author":"K Loughney","year":"1999","unstructured":"Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3\u2019.5\u2019-cyclic nucleotide phosphodiesterase. Gene 234:109\u2013117","journal-title":"Gene"},{"key":"13_CR39_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0031-6997(24)01457-1","volume":"52","author":"KA Lucas","year":"2000","unstructured":"Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375\u2013414","journal-title":"Pharmacol Rev"},{"key":"13_CR40_13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1124\/mol.64.3.533","volume":"64","author":"DH Maurice","year":"2003","unstructured":"Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatany HS, Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression, and targeting cells in the cardiovascular system. Mol Pharmacol 64:533\u2013546","journal-title":"Mol Pharmacol"},{"issue":"Suppl. 5","key":"13_CR41_13","first-page":"S64","volume":"13","author":"A Mazzu","year":"2001","unstructured":"Mazzu A, Nicholls A, Zinny M (2001) Vardenafil: a new highly selective PDE5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged subjects. Int J Impot Res 13(suppl 5):S64 (Abstract)","journal-title":"Int J Impot Res"},{"key":"13_CR42_13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","volume":"177","author":"KT McVary","year":"2007","unstructured":"McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007a) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071\u20131077","journal-title":"J Urol"},{"key":"13_CR43_13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","volume":"177","author":"KT McVary","year":"2007","unstructured":"McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007b) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401\u20131407","journal-title":"J Urol"},{"key":"13_CR44_13","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1016\/S0021-9258(18)31474-1","volume":"268","author":"T Michaeli","year":"1994","unstructured":"Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M (1994) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase deficient Saccharomyces cerevisiae. J Biol Chem 268:12925\u201312932","journal-title":"J Biol Chem"},{"key":"13_CR45_13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.eururo.2006.10.023","volume":"51","author":"S Oger","year":"2007","unstructured":"Oger S, Behr-Roussel D, Gorny D, Denys P, Lebret T, Alexandre L, Giuliano F (2007) Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. Eur Urol 51:772\u2013780","journal-title":"Eur Urol"},{"key":"13_CR46_13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/bmj.288.6410.9","volume":"288","author":"B Ottensen","year":"1984","unstructured":"Ottensen B, Wagner G, Virag R, Fahrenkrug J (1984) Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br J Med 288:9\u201311","journal-title":"Br J Med"},{"key":"13_CR47_13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0022-5347(01)66315-8","volume":"155","author":"H Porst","year":"1996","unstructured":"Porst H (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 155:802\u2013815","journal-title":"J Urol"},{"issue":"Suppl. 3","key":"13_CR48_13","first-page":"S55","volume":"10","author":"M Rajasekaran","year":"1998","unstructured":"Rajasekaran M, Sikka S, Hellstrom W, Doherty P (1998) Evidence for the presence of the type 4 phosphodiesterase in isolated human cavernosal smooth muscle cells. Int J Impot Res 10(suppl 3):S55 (Abstract)","journal-title":"Int J Impot Res"},{"key":"13_CR49_13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJM199201093260203","volume":"326","author":"J Rajfer","year":"1992","unstructured":"Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ (1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to non-adrenergic, non-cholinergic neurotransmission. N Engl J Med 326:90\u201394","journal-title":"N Engl J Med"},{"key":"13_CR50_13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.urology.2004.01.001","volume":"63","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morril B, Wolford ET (2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63:709\u2013715","journal-title":"Urology"},{"key":"13_CR51_13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/01.RES.0000087541.15600.2B","volume":"93","author":"SD Rybulkin","year":"2003","unstructured":"Rybulkin SD, Yan C, Bornfeld KE, Beavo JA (2003) Cyclic GMP phosphodiesterase and smooth muscle function. Circ Res 93:280\u2013291","journal-title":"Circ Res"},{"key":"13_CR52_13","first-page":"1161","volume":"10","author":"D Saighi","year":"2000","unstructured":"Saighi D, Zerbib M, Thiounn N, Flam T, Conquy S, Jacob L, dall'Ava-Santucci J, Debr\u00e9 B, Dinh-Xuan AT (2000) In vitro study of the modulation of human ureteral tonus by nitric oxide and zaprinast, a phosphodiesterase inhibitor. Prog Urol 10:1161\u20131168","journal-title":"Prog Urol"},{"key":"13_CR53_13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1464-410X.2002.03040.x","volume":"90","author":"K Sairam","year":"2002","unstructured":"Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90:836\u2013839","journal-title":"BJU Int"},{"key":"13_CR54_13","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0022-3565(25)23992-1","volume":"271","author":"PJ Silver","year":"1997","unstructured":"Silver PJ, Dundore RL, Bode DC, de Garavilla L, Buchholz RA, van Aller G, Hamel LT, Bacon E, Singh B, Lesher GY (1997) Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J Pharmacol Exp Ther 271:1143\u20131149","journal-title":"J Pharmacol Exp Ther"},{"key":"13_CR55_13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0022-5347(17)32570-3","volume":"152","author":"PJ Smet","year":"1994","unstructured":"Smet PJ, Edyvane KA, Jonasvicius J, Marshall VR (1994) Colocalisation of nitric oxide synthase with vasoactive intestinal peptide, neuropeptide Y and thyrosine hydroxylase in nerves supplying the human ureter. J Urol 152:1292\u20131296","journal-title":"J Urol"},{"key":"13_CR56_13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2165\/00002512-200421090-00001","volume":"21","author":"F Sommer","year":"2004","unstructured":"Sommer F, Engelmann U (2004) Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging 21:555\u2013564","journal-title":"Drugs Aging"},{"key":"13_CR57_13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1368-5031.2004.00128.x","volume":"58","author":"C Stief","year":"2004","unstructured":"Stief C, Porst H, Saenz de Tejada I, Ulbrich E, Beneke M, Vardenafil Study Group (2004) Sustained efficacy and tolerability with vardenafil over two years of treatment in men with erectile dysfunction. Int J Clin Pract 58:230\u2013239","journal-title":"Int J Clin Pract"},{"key":"13_CR58_13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00389789","volume":"24","author":"CG Stief","year":"1996","unstructured":"Stief CG, \u00dcckert S, Truss MC, Becker AJ, Machtens S, Jonas U (1996) A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro. Urol Res 24:333\u2013337","journal-title":"Urol Res"},{"key":"13_CR59_13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/S0022-5347(01)63622-X","volume":"159","author":"CG Stief","year":"1998","unstructured":"Stief CG, \u00dcckert S, Becker AJ, Truss MC, Jonas U (1998) Effects of specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol 159:1390\u20131393","journal-title":"J Urol"},{"key":"13_CR60_13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","volume":"53","author":"CG Stief","year":"2008","unstructured":"Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236\u20131244","journal-title":"Eur Urol"},{"key":"13_CR61_13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/BF00191209","volume":"12","author":"A Taher","year":"1994","unstructured":"Taher A, Schulz-Knappe P, Meyer M, Truss MC, Forssmann WG, Stief CG, Jonas U (1994) Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J Urol 12:286\u2013291","journal-title":"World J Urol"},{"key":"13_CR62_13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/BF01275154","volume":"15","author":"A Taher","year":"1997","unstructured":"Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG (1997) Cyclic nucleotide phosphodiesterase isoenzymes in human cavernous smooth muscle. World J Urol 15:32\u201335","journal-title":"World J Urol"},{"issue":"Suppl. 1","key":"13_CR63_13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1569-9056(02)80588-7","volume":"1","author":"U Thadani","year":"2002","unstructured":"Thadani U, Mazzu A (2002) Exercise-induced ischemia was not adversely affected by vardenafil during exercise stress test in men with coronary artery disease. Eur Urol 1(suppl 1):151 (Abstract)","journal-title":"Eur Urol"},{"key":"13_CR64_13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejphar.2008.06.055","volume":"591","author":"HA Toque","year":"2008","unstructured":"Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, de Nucci G (2008) Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor, lodenafil carbonate, on human and rabbit corpus cavernosum. Eur J Pharmacol 591:189\u2013195","journal-title":"Eur J Pharmacol"},{"key":"13_CR65_13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0090-4295(94)80058-8","volume":"44","author":"MC Truss","year":"1994","unstructured":"Truss MC, Becker AJ, Djamillian MH, Stief CG, Jonas U (1994) Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 44:553\u2013556","journal-title":"Urology"},{"key":"13_CR66_13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00304074","volume":"24","author":"MC Truss","year":"1996","unstructured":"Truss MC, \u00dcckert S, Stief CG, Kuczyk MA, Jonas U (1996a) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: I. Identification and characterization. Urol Res 24:123\u2013128","journal-title":"Urol Res"},{"key":"13_CR67_13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00304075","volume":"24","author":"MC Truss","year":"1996","unstructured":"Truss MC, \u00dcckert S, Stief CG, Kuczyk MA, Jonas U (1996b) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: II. Effect of various PDE-inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 24:129\u2013134","journal-title":"Urol Res"},{"key":"13_CR68_13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s003450100221","volume":"19","author":"MC Truss","year":"2001","unstructured":"Truss MC, Stief CG, \u00dcckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19:344\u2013350","journal-title":"World J Urol"},{"issue":"Suppl. 4","key":"13_CR69_13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0022-5347(09)60437-7","volume":"181","author":"S \u00dcckert","year":"2009","unstructured":"\u00dcckert S, Sandner P, Sigl K, Ulbrich E, Stief CG, Kuczyk MA (2009) Is there a role of the phosphodiesterase type 5 (PDE5) in the control of detrusor smooth muscle? A functional and molecular biology study. J Urol 181(suppl 4):152 (Abstract)","journal-title":"J Urol"},{"key":"13_CR70_13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/PL00007090","volume":"19","author":"S \u00dcckert","year":"2001","unstructured":"\u00dcckert S, K\u00fcthe A, Stief CG, Jonas U (2001a) Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19:14\u201322","journal-title":"World J Urol"},{"key":"13_CR71_13","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/S0022-5347(05)65621-2","volume":"166","author":"S \u00dcckert","year":"2001","unstructured":"\u00dcckert S, K\u00fcthe A, Jonas U, Stief CG (2001b) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484\u20132490","journal-title":"J Urol"},{"key":"13_CR72_13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00345-003-0394-4","volume":"22","author":"S \u00dcckert","year":"2004","unstructured":"\u00dcckert S, Hedlund P, Waldkirch E, Sohn M, Jonas U, Andersson KE, Stief CG (2004) Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol 22:261\u2013266","journal-title":"World J Urol"},{"key":"13_CR73_13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2005.12.050","volume":"49","author":"S \u00dcckert","year":"2006","unstructured":"\u00dcckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49:740\u2013745","journal-title":"Eur Urol"}],"container-title":["Handbook of Experimental Pharmacology","Phosphodiesterases as Drug Targets"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-17969-3_13.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:38:22Z","timestamp":1741264702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-17969-3_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9783642179686","9783642179693"],"references-count":73,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-17969-3_13","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}